Please assess the completion status of the following clinical trial:

Trial Title: Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a histologic or cytologic diagnosis of carcinoma of the gastroesophageal junction or esophagus;~* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria;~* Overexpression of EGFR defined by immunohistochemistry (3+) or gene amplification by fluorescence in-situ hybridisation;~* Have progressed after one chemotherapy regimen;~* Age 18-75 years old with performance status of 0 to 2~Exclusion Criteria:~* Prior targeted therapy with erlotinib, gefitinib, and so on~* Evidence of clinically active Interstitial Lung Diseases (Patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded).~* Known severe hypersensitivity to icotinib or any of the excipients of this product.~* Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the subject to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): Icotinib: 250 mg is administered orally three times per day, until disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).